Financial Performance - Total revenues for Q2 2024 reached $72 million, representing a 49% increase compared to Q2 2023 [1][3] - Year-to-date (YTD) 2024 total revenues amounted to $139 million, a 55% increase from YTD 2023 [1] - Net income for YTD 2024 was $9 million, with a non-GAAP net income of $29 million [1] Revenue Breakdown - Royalties from collaborations totaled $25.6 million in Q2 2024, up 34% from the previous year [3] - Revenue from collaborations and services increased by 132% to $26 million in Q2 2024 [3] - Net revenue from Afrezza was $16.3 million, a 20% increase year-over-year, while V-Go net revenue decreased by 7% to $4.5 million [3] Cost and Expenses - Commercial product gross margin improved to 73% in Q2 2024 from 72% in Q2 2023, driven by higher Afrezza net revenue [4] - Research and development (R&D) expenses rose to $11.8 million in Q2 2024, up from $6.5 million in Q2 2023, primarily due to increased development activities [5] - Selling expenses decreased to $11.5 million in Q2 2024 from $14 million in Q2 2023, attributed to a sales force restructuring [6] Clinical Development - The company advanced two orphan lung programs to human studies, with MNKD-101 Phase 3 clinical trial activities initiated and MNKD-201 Phase 1 clinical trial on schedule [1][20][21] - Afrezza INHALE-3 trial showed significant improvements in achieving target A1c levels compared to standard care [20] - MNKD-201 Phase 1 trial in healthy volunteers is underway, with results expected in Q4 2024 [23] Cash and Investments - As of June 30, 2024, the company had cash, cash equivalents, and investments totaling $261.9 million [14]

LearnAboutNTM.com provides information and resources for patients and caregiversSite launch in support of World NTM Awareness Day, August 4 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today the launch of an educational website designed to raise awareness of nontu ...

LearnAboutNTM.com provides information and resources for patients and caregiversSite launch in support of World NTM Awareness Day, August 4 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today the launch of an educational website designed to raise awareness of nont ...

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), announced today that it will report its second quarter 2024 financial results before the market opens on Wednesday, August 7, 2024. A press release detailing the quarterly results will be issued the same day approximately one hour prior to the webcast. MannKind will host a webcast beginning at 9:00 a.m. Eastern Time for investors, media, and the general public. Participating in the conference c ...

Group 1 - MannKind Corporation will report its second quarter 2024 financial results on August 7, 2024, before market opens [1] - A press release detailing the quarterly results will be issued approximately one hour prior to the webcast [1] - The webcast will begin at 9:00 a.m. Eastern Time and will be accessible via MannKind's website [1] Group 2 - MannKind focuses on developing and commercializing innovative inhaled therapeutic products for serious unmet medical needs [2] - The company aims to address diseases such as diabetes, NTM lung disease, pulmonary fibrosis, and pulmonary hypertension [2] - MannKind utilizes dry-powder formulations and inhalation devices for rapid and convenient delivery of medicines [2]

Investors might want to bet on MannKind (MNKD) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Since a cha ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is MannKind (MNKD) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.MannKind is a member of the Medical sector. This group includes 1025 individual stocks and currently holds a Zacks Sector Rank of #5. The Zacks Sector Rank considers 16 different groups, ...

Shares of MannKind (MNKD) have been strong performers lately, with the stock up 22.7% over the past month. The stock hit a new 52-week high of $5.93 in the previous session. MannKind has gained 60.2% since the start of the year compared to the 7% move for the Zacks Medical sector and the -0.8% return for the Zacks Medical - Biomedical and Genetics industry.What's Driving the Outperformance?The stock has a great record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in an ...

Study proves inhaled insulin is as effective as usual care (primarily automated insulin delivery pumps or multiple daily injections) for adults living with T1D meeting the primary endpointPatients utilizing inhaled insulin reached target A1c (less than 7%) 30% of the time compared to 17% with usual care and 24% had time-in-range (TIR) above 70% with no increased hypoglycemia compared with 13% with usual careMore than 50% of subjects at the end of the study expressed an interest in continuing to use Afrezza® ...